US-based biopharmaceutical company Kashiv Biosciences has reported that a Phase I trial of its 125mg/mL pre-filled ... In the trial, the abatacept biosimilar candidate KSHB002 showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback